2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-109590A
    Arachidonic acid sodium salt 6610-25-9 ≥99.0%
    Arachidonic acid (Immunocytophyt) sodium salt is a polyunsaturated omega-6 fatty acid and a major constituent of biomembranes. Arachidonic acid sodium salt also acts as the substrate for various lipid mediators, such as prostaglandins (PGs). Arachidonic acid sodium salt improves cognitive response and cardiovascular function.
    Arachidonic acid sodium salt
  • HY-118010A
    (+)-Norfenfluramine hydrochloride 37936-89-3 99.77%
    (+)-Norfenfluramine hydrochloride, a major hepatic metabolite of (+)-fenfluramine, is a selective 5-HT2B receptor agonist (Ki: 11.2 nM). (+)-Norfenfluramine hydrochloride potently stimulates the hydrolysis of inositol phosphates and increases intracellular Ca2+. (+)-Norfenfluramine hydrochloride can be used for the research of primary pulmonary hypertension and valvular heart disease.
    (+)-Norfenfluramine hydrochloride
  • HY-W006957
    N6-(2-Hydroxyethyl)adenosine 4338-48-1 99.85%
    N6-(2-Hydroxyethyl)adenosine is a purine nucleoside analog. N6-(2-Hydroxyethyl)adenosine inhibits NF-κB/Smad signaling pathway, exhibits anti-hyperglycemia, antioxidant, antitumor and anti-inflammatory and insecticidal activities. N6-(2-Hydroxyethyl)adenosine is orally active.
    N6-(2-Hydroxyethyl)adenosine
  • HY-W004284S1
    Heptadecanoic acid-d33 352431-41-5 ≥99.0%
    Heptadecanoic acid-d33 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
    Heptadecanoic acid-d33
  • HY-17378
    Dabigatran (ethyl ester) 429658-95-7
    Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
    Dabigatran (ethyl ester)
  • HY-B0908
    Meticrane 1084-65-7 98.93%
    Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.
    Meticrane
  • HY-B1295
    Lithium citrate tetrahydrate 6080-58-6 ≥98.0%
    Lithium citrate (Litarex) tetrahydrate is a natural preservative and food tartness enhancer. Lithium citrate tetrahydrate induces apoptosis and cell cycle arrest at G2/M phase and S phase in HaCaT cells. Lithium citrate tetrahydrate cause oxidative damage of the liver by means of the decrease of antioxidative enzyme activities. Lithium citrate tetrahydrate is also an acidulant, emulsifier, sequestrant and buffering agent widely used across many industries.
    Lithium citrate tetrahydrate
  • HY-13422A
    Zatebradine 85175-67-3 99.27%
    Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively.
    Zatebradine
  • HY-W004580
    5,5'-Dicarboxy-2,2'-bipyridine 1802-30-8 ≥98.0%
    5,5'-Dicarboxy-2,2'-bipyridine is a niacin derivative, which is promising for research of hypercholesterolemia, hyperlipidemia, and cardiovascular disease.
    5,5'-Dicarboxy-2,2'-bipyridine
  • HY-15798
    UNC2881 1493764-08-1 99.79%
    UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC50s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research.
    UNC2881
  • HY-16265
    JI-101 900573-88-8 99.78%
    JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.
    JI-101
  • HY-B0612
    Lercanidipine 100427-26-7 99.65%
    Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research.
    Lercanidipine
  • HY-P1348
    GLP-1 moiety from Dulaglutide 1197810-60-8 99.59%
    GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury.
    GLP-1 moiety from Dulaglutide
  • HY-101987
    BW 245C 72814-32-5 ≥99.0%
    BW 245C is a prostanoid DP-receptor (DP1) agonist, used to treat stroke.
    BW 245C
  • HY-105685
    SRX246 512784-93-9 99.76%
    SRX246 is a potent, CNS-penetrant, highly selective, orally bioavailable vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V1a). SRX246 has no interaction at V1b and V2 receptors. SRX246 also displays negligible binding at 64 others receptors classes, including 35 G-proteincoupled receptors. SRX246 can be used for treatment of stress-related disorders.
    SRX246
  • HY-P99017
    Eptinezumab 1644539-04-7 99.90%
    Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab can be used in the study of preventing migraines.
    Eptinezumab
  • HY-B0655
    Zofenopril calcium 81938-43-4 99.76%
    Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A).
    Zofenopril calcium
  • HY-100897
    Sulodexide 57821-29-1
    Sulodexide is an orally active mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease.
    Sulodexide
  • HY-109058
    Firibastat 648927-86-0 ≥98.0%
    Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats.
    Firibastat
  • HY-133016
    M8891 1464842-09-8 99.36%
    M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC50 of 54 nM and a Ki of 4.33 nM. M8891 does not inhibit MetAP-1 (IC50>10 µM). M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity.
    M8891
Cat. No. Product Name / Synonyms Application Reactivity